Table 2. Intervention coverage and prevalence of ocular Chlamydia trachomatis infection at baseline, 12 and 24 months by subkebele and treatment arm.
| Prevalence of ocular Chlamydia trachomatis infection in children 0–9 years | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Arma | Subkebele | Antibiotic treatment coverage ages 0–9 | Household latrine coverageb,c | Baseline | 12 Months | 24 Months | |||||
| % | n/N | % | n/N | % | n/N | % | n/N | % | n/N | ||
| Single antibiotic treatment only | 1 | 84.4 | (114/135) | No intervention with latrines | 47.9 | (23/48) | 20.0 | (10/50) | 38.0 | (19/50) | |
| 2 | 95.7 | (265/277) | 58.9 | (33/56) | 30.2 | (16/53) | 34.0 | (17/50) | |||
| 3 | 81.0 | (64/79) | 51.0 | (25/49) | 23.1 | (9/39) | 12.0 | (6/50) | |||
| 4 | 88.2 | (75/85) | 47.9 | (23/48) | 26.0 | (13/50) | 18.9 | (10/53) | |||
| 5 | 98.6 | (144/146) | 5.7 | (3/53) | 4.0 | (2/50) | 1.9 | (1/52) | |||
| 6 | 97.5 | (115/118) | 50.0 | (28/56) | 13.5 | (7/52) | 16.0 | (8/50) | |||
| 7 | 100.0 | (119/119) | 54.0 | (27/50) | 7.8 | (4/51) | 4.1 | (2/49) | |||
| 8 | 100.0 | (129/129) | 8.2 | (4/49) | 8.0 | (4/50) | 6.0 | (3/50) | |||
| 9 | 97.4 | (149/153) | 28.8 | (15/52) | 2.0 | (1/50) | 8.0 | (4/50) | |||
| 10 | 95.0 | (153/161) | 54.0 | (27/50) | 25.5 | (13/51) | 10.0 | (5/50) | |||
| 11 | 95.6 | (108/113) | 61.1 | (33/54) | 19.6 | (10/51) | 17.6 | (9/51) | |||
| 12 | 96.6 | (112/116) | 47.9 | (23/48) | 5.9 | (3/51) | 8.3 | (4/48) | |||
| Average (95% CI) | 94.2 | (90.2–98.1) | 43.0 | (31.1–54.8) | 15.5 | (9.3–21.7) | 14.6 | (7.4–21.8) | |||
| Single antibiotic treatment plus intensive latrine promotion | 13 | 86.3 | (107/124) | 87.7 | (221/252) | 54.2 | (26/48) | 7.7 | (4/52) | 16.0 | (8/50) |
| 14 | 89.9 | (285/317) | 53.6 | (141/263) | 72.5 | (37/51) | 13.7 | (7/51) | 22.0 | (11/50) | |
| 15 | 90.2 | (74/82) | 75.5 | (176/233) | 38.0 | (19/50) | 7.7 | (4/52) | 10.5 | (6/57) | |
| 16 | 84.4 | (195/231) | 77.5 | (338/436) | 57.1 | (28/49) | 26.0 | (13/50) | 16.0 | (8/50) | |
| 17 | 95.2 | (60/63) | 95.0 | (208/219) | 26.0 | (13/50) | 4.0 | (2/50) | 3.9 | (2/51) | |
| 18 | 68.4 | (65/95) | 82.7 | (177/214) | 39.6 | (21/53) | 13.5 | (7/52) | 16.0 | (8/50) | |
| 19 | 74.3 | (104/140) | 74.9 | (209/279) | ND | 15.5 | (9/58) | 34.0 | (17/50) | ||
| 20 | 90.4 | (75/83) | 73.0 | (260/356) | 74.0 | (37/50) | 25.5 | (13/51) | 22.0 | (11/50) | |
| 21 | 92.6 | (63/68) | 92.4 | (244/264) | 34.0 | (17/50) | 12.8 | (6/47) | 3.9 | (2/51) | |
| 22 | 87.8 | (101/115) | 66.5 | (220/331) | 28.3 | (15/53) | 11.1 | (6/54) | 16.0 | (8/50) | |
| 23 | 80.2 | (77/96) | 80.6 | (323/401) | 44.4 | (24/54) | 2.0 | (1/51) | 0.0 | (0/48) | |
| 24 | 86.5 | (218/252) | 92.3 | (216/234) | 31.9 | (15/47) | 14.0 | (7/50) | 17.6 | (9/51) | |
| Average (95% CI) | 85.5 | (80.6–90.5) | 79.3 | (71.7–86.9) | 45.5 | (34.1–56.8) | 12.8 | (8.1–17.5) | 14.8 | (8.9–20.8) | |
a
All subkebeles in both treatment arms were treated with a single mass azithromycin distribution at baseline.
b
Results of population and household census, not latrine survey.
c
New latrine construction was not measured in single treatment only arm.
ND: No data: examination team conducted clinical exam and swabbed the wrong subkebele.